Shopping Cart
- Remove All
- Your shopping cart is currently empty
WSF1-IN-1 (compound 136) is an orally active inhibitor of WSF1, designed for studying WSF1-related tumors in patients with Wolfram syndrome (WS). In HepG2 parental and HepG2 WFS1 KO cell lines, WSF1-IN-1 has shown IC50 values of 0.33 μM and >27 μM, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $235 | 5 days |
Description | WSF1-IN-1 (compound 136) is an orally active inhibitor of WSF1, designed for studying WSF1-related tumors in patients with Wolfram syndrome (WS). In HepG2 parental and HepG2 WFS1 KO cell lines, WSF1-IN-1 has shown IC50 values of 0.33 μM and >27 μM, respectively. |
In vitro | WSF1-IN-1 (compound 136) demonstrates selective inhibition with IC50 values of >27 μM for Hek293 empty vectors and 0.03 μM for Hek293 WFS1 over-expressors. In cell viability assays, the compound shows IC50s of 0.05 μM for Colo-205 Control shRNA, >9 μM for Colo-205 WSF1 shRNA, 0.08 μM for DU4415 Control shRNA, 6.1 μM for DU4415 WSF1 shRNA, 0.26 μM for HepG2 Control shRNA, and 2.2 μM for HepG2 WSF1 shRNA, respectively[1]. |
In vivo | WSF1-IN-1 (compound 136, 100 mpk qd, orally, 14 days) demonstrated a tumor growth inhibition (TGI) of 106.65% in NSCLC patient-derived xenograft OD33996 nu/nu mice[1]. |
Alias | WSF1-IN-1 |
Molecular Weight | 446.438 |
Formula | C20H21F3N8O |
Cas No. | 2379577-82-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.